These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19361757)

  • 1. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
    Martínez C; Solano C; Ferrá C; Sampol A; Valcárcel D; Pérez-Simón JA;
    Biol Blood Marrow Transplant; 2009 May; 15(5):639-42. PubMed ID: 19361757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
    Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective.
    Schub N; Günther A; Schrauder A; Claviez A; Ehlert C; Gramatzki M; Repp R
    Bone Marrow Transplant; 2011 Jan; 46(1):143-7. PubMed ID: 20348971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
    Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
    Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation.
    Bertz H; Spyridonidis A; Wäsch R; Grüllich C; Egger M; Finke J
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1563-70. PubMed ID: 19896080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
    Ye CX; Sun J; Liu QF; Qu H; Xu D; Zhang Y; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2224-6. PubMed ID: 19114364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
    Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
    Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease.
    Meunier M; Bulabois CE; Thiebaut-Bertrand A; Itzykson R; Carre M; Carras S; Garban F; Cahn JY
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1451-4. PubMed ID: 24910381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab.
    Schnitzler M; Hasskarl J; Egger M; Bertz H; Finke J
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):910-8. PubMed ID: 19589480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD).
    Carella AM; Beltrami G; Scalzulli PR; Carella AM; Corsetti MT
    Bone Marrow Transplant; 2004 Jan; 33(1):131-2. PubMed ID: 14566330
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute gastrointestinal graft-versus-host disease in pediatric patients: serum albumin on day 5 from initiation of therapy correlates with nonrelapse mortality and overall survival.
    Goussetis E; Paisiou A; Kitra V; Peristeri I; Vessalas G; Stefanaki K; Panayotou I; Giamaiou K; Kontou E; Kitzoni M; Dimopoulou MN; Karkelis S; Kafritsa Y; Rapsomaniki E; Papassotiriou I; Tsirigotis P; Roma E; Graphakos S
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1058-66. PubMed ID: 21073975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
    Das-Gupta EP; Russell NH; Shaw BE; Pearce RM; Byrne JL
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):724-33. PubMed ID: 17531783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD.
    Perfetti P; Carlier P; Strada P; Gualandi F; Occhini D; Van Lint MT; Ibatici A; Lamparelli T; Bruno B; Raiola AM; Dominietto A; Di Grazia C; Bregante S; Zia S; Ferrari GM; Stura P; Pogliani E; Bacigalupo A
    Bone Marrow Transplant; 2008 Nov; 42(9):609-17. PubMed ID: 18660840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracorporeal photopheresis: a useful therapy for patients with steroid-refractory acute graft-versus-host disease but not for the prevention of the chronic form.
    Rubegni P; Feci L; Poggiali S; Marotta G; D'Ascenzo G; Murdaca F; Fimiani M
    Br J Dermatol; 2013 Aug; 169(2):450-7. PubMed ID: 23534380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
    Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
    Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
    van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.